Sarissa Capital Challenges Amarin’s Management; Nemaura Receives Provisional Purchase Order from TPMENA

A series of cardiometabolic-related news items have been observed: Sarissa Capital Management LP announced plans to initiate the process of holding a special meeting of Amarin shareholders to reorganize the company’s Board; and Nemaura announced it received a provisional purchase order from its Middle East/North Africa licensee, TPMENA, for the non-invasive sugarBEAT CGM system. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.